These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 22394596)

  • 41. Pralatrexate, a new hope for aggressive T-cell lymphomas?
    Rueda A; Casanova M; Quero C; Medina-Pérez A
    Clin Transl Oncol; 2009 Apr; 11(4):215-20. PubMed ID: 19380298
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
    Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
    Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Small Primary Cutaneous γδT-Cell Lymphoma Lesions Successfully Treated With Pralatrexate.
    Imataki O; Uchida S; Yokokura S; Uemura M; Kadowaki N
    Clin Nucl Med; 2019 Feb; 44(2):e85-e86. PubMed ID: 30516664
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A phase II study of pralatrexate with vitamin B12 and folic acid supplementation for previously treated recurrent and/or metastatic head and neck squamous cell cancer.
    Ho AL; Lipson BL; Sherman EJ; Xiao H; Fury MG; Apollo A; Seetharamu N; Sima CS; Haque S; Lyo JK; Sales R; Cox L; Pfister DG
    Invest New Drugs; 2014 Jun; 32(3):549-54. PubMed ID: 24566705
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pralatrexate injection for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma.
    Jennifer C Z; Sara Mohamed J; Salma A; Francine F
    Expert Rev Hematol; 2020 Jun; 13(6):577-583. PubMed ID: 32293930
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
    Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
    Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pralatrexate in relapsed/refractory T-cell lymphoma: a retrospective multicenter study.
    Bhurani M; Admojo L; Van Der Weyden C; Twigger R; Bazargan A; Quach H; Zimet A; Coyle L; Lindsay J; Radeski D; Hawkes E; Kennedy G; Irving I; Gutta N; Trotman J; Yeung J; Dunlop L; Hua M; Giri P; Yuen S; Panicker S; Moreton S; Khoo L; Scott A; Kipp D; McQuillan A; McCormack C; Dickinson M; Prince HM
    Leuk Lymphoma; 2021 Feb; 62(2):330-336. PubMed ID: 33026266
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma.
    Foss F; Advani R; Duvic M; Hymes KB; Intragumtornchai T; Lekhakula A; Shpilberg O; Lerner A; Belt RJ; Jacobsen ED; Laurent G; Ben-Yehuda D; Beylot-Barry M; Hillen U; Knoblauch P; Bhat G; Chawla S; Allen LF; Pohlman B
    Br J Haematol; 2015 Mar; 168(6):811-9. PubMed ID: 25404094
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T-Cell Lymphoma and Lymphomatoid Papulosis.
    Duvic M; Tetzlaff MT; Gangar P; Clos AL; Sui D; Talpur R
    J Clin Oncol; 2015 Nov; 33(32):3759-65. PubMed ID: 26261247
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy.
    Kelly K; Azzoli CG; Zatloukal P; Albert I; Jiang PY; Bodkin D; Pereira JR; Juhász E; Iannotti NO; Weems G; Koutsoukos T; Patel JD
    J Thorac Oncol; 2012 Jun; 7(6):1041-8. PubMed ID: 22534814
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Other Chemotherapeutic Agents in Cutaneous T-Cell Lymphoma.
    Chung CG; Poligone B
    Dermatol Clin; 2015 Oct; 33(4):787-805. PubMed ID: 26433850
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
    Advani RH; Ansell SM; Lechowicz MJ; Beaven AW; Loberiza F; Carson KR; Evens AM; Foss F; Horwitz S; Pro B; Pinter-Brown LC; Smith SM; Shustov AR; Savage KJ; Vose JM
    Br J Haematol; 2016 Feb; 172(4):535-44. PubMed ID: 26627450
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pralatrexate-induced tumor cell apoptosis in the epidermis of a patient with HTLV-1 adult T-cell lymphoma/leukemia causing skin erosions.
    Marneros AG; Grossman ME; Silvers DN; Husain S; Nuovo GJ; MacGregor-Cortelli B; Neylon E; Patterson M; O'Connor OA; Zain JM
    Blood; 2009 Jun; 113(25):6338-41. PubMed ID: 19389878
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Forodesine in the treatment of cutaneous T-cell lymphoma.
    Lewis DJ; Duvic M
    Expert Opin Investig Drugs; 2017 Jun; 26(6):771-775. PubMed ID: 28447489
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors.
    Fury MG; Krug LM; Azzoli CG; Sharma S; Kemeny N; Wu N; Kris MG; Rizvi NA
    Cancer Chemother Pharmacol; 2006 May; 57(5):671-7. PubMed ID: 16136310
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pralatrexate: a novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses.
    Hui J; Przespo E; Elefante A
    J Oncol Pharm Pract; 2012 Jun; 18(2):275-83. PubMed ID: 21956523
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Long-term efficacy and safety of alemtuzumab in advanced primary cutaneous T-cell lymphomas.
    de Masson A; Guitera P; Brice P; Moulonguet I; Mouly F; Bouaziz JD; Battistella M; Madelaine I; Roux J; Ram-Wolff C; Cayuela JM; Bachelez H; Bensussan A; Michel L; Bagot M
    Br J Dermatol; 2014 Mar; 170(3):720-4. PubMed ID: 24438061
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase 1 study of oral TAS-102 in patients with refractory metastatic colorectal cancer.
    Bendell JC; Rosen LS; Mayer RJ; Goldman JW; Infante JR; Benedetti F; Lin D; Mizuguchi H; Zergebel C; Patel MR
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):925-32. PubMed ID: 26370544
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study.
    Burris HA; Flinn IW; Patel MR; Fenske TS; Deng C; Brander DM; Gutierrez M; Essell JH; Kuhn JG; Miskin HP; Sportelli P; Weiss MS; Vakkalanka S; Savona MR; O'Connor OA
    Lancet Oncol; 2018 Apr; 19(4):486-496. PubMed ID: 29475723
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Current and emerging treatment strategies for cutaneous T-cell lymphoma.
    Lansigan F; Foss FM
    Drugs; 2010 Feb; 70(3):273-86. PubMed ID: 20166766
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.